Showing results (101-110 of 159) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumorsVictoria Roulstone, Khurum Khan, Hardev S Pandha, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signalingVictoria Roulstone, Joan Kyula, Elizabeth Appleton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 27, 2012
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated miceDiana M Rommelfanger, Marta Compte, Marta C Grau, et al.
Experimental Cell Research|May 1, 2007
The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat modelNicolas Larmonier, Dominique Cathelin, Claire Larmonier, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2020
Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell ResponsesAmanda L Huff, Laura Evgin, Jill Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responsesRichard Harrop, Noel Drury, William Shingler, et al.
Cancer Research|June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapyMarka Crittenden, Michael Gough, John Chester, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 22, 2025
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapyAlexa Veliz Rios, Muriel Metko, Jason Tonne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Translational Oncology|August 14, 2022
Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancersAruna Korlimarla, Hari Ps, Jyoti Prabhu, et al.
Pageof 16